

A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19

[ijidonline.com/article/S1201-9712\(20\)30604-4/fulltext](https://www.ijidonline.com/article/S1201-9712(20)30604-4/fulltext)



Open Access Published: July 31, 2020 DOI: <https://doi.org/10.1016/j.ijid.2020.07.059>



PlumX Metrics

To the Editor:

In response:

We thank those submitting letters. It is important to critically review COVID-19 experience in a peer-reviewed, non-politicized process, and we fully support appropriately powered double-blind, randomized trials to address questions on COVID-19 clinical management. Many letters discussed several similar points, which we will address jointly. Corticosteroids (MPD) were controlled for in the multivariate and propensity analyses as were age and comorbidities, including cardiac disease and severity of illness. Age was an independent risk factor associated with mortality. We do feel that steroids have a role in reducing mortality for COVID-19 and were first to publish this (

Fadel et al., 2020

), however in this study, HCQ was independently associated with decreased mortality, a distinct benefit from the steroid effect. We agree with Wiseman that prospective evaluation of a stage-and-age-nuanced approach to COVID-19 that exploits the multiple mechanisms of HCQ and synergy with MPD is needed. In response to Malviya, we reported 91% of all patients began treatment within two days of admission. We agree that early therapy is of most benefit; however, we do not have information on the duration of symptoms prior to hospitalization. The mSOFA has been validated in other studies (

de Grooth et al., 2017

,

Grissom et al., 2010

); moreover, we also used hypoxia as an independent marker of disease severity. In

response to Thornton, HCQ was used throughout the study period, limiting time bias. We used dosages that followed FDA guidelines, with monitoring for cardiac arrhythmias. All centers used the same treatment guideline minimizing treatment bias. The protocol we used was previously published (

Fadel et al., 2020

). In response to Atkinson, patients assigned to the HCQ group had a moderate and severe illness at presentation, which would favor worse outcomes with HCQ. The exclusion of patients with premorbid risk for cardiac toxicity is similar to clinical trials of many other drugs such as remdesivir, where individuals with severe liver or kidney disease were excluded (

Clinical Trial, 2020

).

Importantly, in response to Rosenberg, our study differed from other studies, including randomized controlled trials (RCTs), in a variety of ways, including the number of patients, comorbidities, the severity of illness and dosage and timing of administration of HCQ (

WHO, 2020

,

New Indian Express, 2020

,

Mikami et al., 2020

). Prior studies have major limitations with timing, dosing, cardiac AE monitoring, and therapeutic windows. To date, there has been no properly designed and powered RCT that evaluates HCQ treatment for COVID-19. Concerning our comments about the Rosenberg paper, a variety of serious limitations in that paper should be corrected on the record. The critical limitation, among many others, is that patients receiving HCQ with or without azithromycin (AZM) were overall sicker on presentation and had multiple other risk factors; Black or Hispanic patients were likely to receive HCQ or AZM (mortality is significantly higher in these groups). Patients receiving HCQ were more likely to be obese, diabetic, have chronic lung disease, and cardiovascular conditions, yet these sicker patients had approximately the same mortality rates compared to patients with a milder course of the disease and fewer risk factors. However, the authors incorrectly conclude that “there are no significant benefits.” It is noteworthy that HCQ was associated with a significant survival benefit in a larger cohort of patients from New York City, as reported by

Mikami et al. (2020)

.

In these unprecedented times, the role, cost-benefit, and availability of repurposed agents such as HCQ and newer drugs such as remdesivir should be urgently evaluated in an impartial manner. Remdesivir is a novel drug with a novel approach and has a place in the COVID-19 treatment formulary; however, it is expensive, and there is limited availability outside of the United States (

Forbes, 2020

,

Finley, 2020

).

Our paper's overarching theme is that a safe dosage and early utilization of hydroxychloroquine reduced mortality in hospitalized patients. Similar published large cohort studies support our findings from New York City and France (

Mikami et al., 2020

,

Lagier et al., 2020

) As stated in our paper, further prospective studies are needed.

Conflict of interest

No conflict of interest to declare.

Ethical approval

Approval was not required.

References

1. <https://clinicaltrials.gov/ct2/show/NCT04280705>

View in Article

Google Scholar

- 2.

- de Grooth H.-J.
- Geenen I.L.
- Girbes A.R.
- Vincent J.-L.
- Parienti J.-J.
- Heleen M.

Oudemans-van Straaten SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis.

Crit Care. 2017; 21: 38<https://doi.org/10.1186/s13054-017-1609-1>

View in Article

Google Scholar

3.

- Fadel R.
- Morrison A.R.
- Vahia A.
- Smith Z.R.
- Chaudhry Z.
- Bhargavaet P.
- et al.

Early short course corticosteroids in hospitalized patients with COVID-19.

Clin Infect Dis cia. 2020; ([published online ahead of print, 2020 May 19]):
a601<https://doi.org/10.1093/cid/ciaa60>

[View in Article](#)

[Google Scholar](#)

4. Finley, A. The Politics of Hydroxychloroquine: Trump touted it, so Biden denounces it. The FDA has suspended a permit for its use. Let doctors decide.

[View in Article](#)

[Google Scholar](#)

5. <https://www.forbes.com/sites/iainmartin/2020/07/01/us-buys-the-world-supply-of-breakthrough-coronavirus-drug-remdesivir/#7556focf547>

[View in Article](#)

[Google Scholar](#)

6.

- Grissom C.K.
- Brown S.M.
- Kuttler K.G.
- Boltax J.P.
- Jones J.
- Jephson A.R.
- et al.

A modified sequential organ failure assessment (MSOFA) Score for Critical Care Triage Disaster.

Med Public Health Prep. 2010; 4<https://doi.org/10.1001/dmp.2010.40> paper

[View in Article](#)

[Google Scholar](#)

7.

- Lagier J.C.
- Million M.
- Gautret P.
- Colson P.
- Cortaredona S.
- Giraud-Gatineau A.
- et al.

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis.

Travel Med Infect Dis. 2020; 1017: 91

[View in Article](#)

[Google Scholar](#)

8.

- Mikami T.
- Miyashita H.
- Yamada T.
- Harrington M.
- Steinberg D.
- Dunn A.
- et al.

Risk factors for mortality in patients with COVID-19 in New York City.

J Gen Intern Med. 2020;

[View in Article](#)

[Google Scholar](#)

9. <https://www.newindianexpress.com/nation/2020/may/29/icmr-writes-to-who-disagreeing-with-hcq-assessment-officials-say-international-trial-dosage-four-ti-2149702.html>

[View in Article](#)

[Google Scholar](#)

10. <https://www.who.int/publications/m/item/informal-consultation-on-the-dose-of-chloroquine-and-hydroxychloroquine-for-the-solidarity-clinical-trial---8-april-2020>

[View in Article](#)

[Google Scholar](#)

Article Info

Publication History

Published online: July 31, 2020

Received: July 21, 2020

Identification

DOI: <https://doi.org/10.1016/j.ijid.2020.07.059>

Copyright

© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

User License

[Creative Commons Attribution – NonCommercial – NoDerivs \(CC BY-NC-ND 4.0\)](#) | [How you can reuse](#) 

ScienceDirect

[Access this article on ScienceDirect](#)

Linked Article

- [Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19](#)
International Journal of Infectious Diseases Vol. 97
 - [In Brief](#)
 - [Full-Text](#)
 - [PDF](#)Open Access
- [Hydroxychloroquine in COVID-19: taking care of statistic to take care of patients](#)
International Journal of Infectious Diseases
 - [In Brief](#)
 - [Full-Text](#)
 - [PDF](#)Open Access
- [Problems with the analysis in “Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19”](#)
International Journal of Infectious Diseases
 - [In Brief](#)
 - [Full-Text](#)
 - [PDF](#)Open Access

- [Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?](#)

International Journal of Infectious Diseases

- [In Brief](#)
- [Full-Text](#)
- [PDF](#)

Open Access

- [Re: Arshad S, Kilgore P, Chaudhry ZS et al. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19. Int J Infect Dis: 2020. Epub 2020 Jul 1 <http://doi.org/10.1016/j.ijid.2020.06.099>](#)

International Journal of Infectious Diseases

- [In Brief](#)
- [Full-Text](#)
- [PDF](#)

Open Access

- [Comment on Arshad et al: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19](#)

International Journal of Infectious Diseases

- [In Brief](#)
- [Full-Text](#)
- [PDF](#)

Open Access

- [The continued dilemma about usage of Hydroxychloroquine: Respite is in randomized control trials](#)

International Journal of Infectious Diseases

- [In Brief](#)
- [Full-Text](#)
- [PDF](#)

Open Access

- [Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19](#)

International Journal of Infectious Diseases

- [In Brief](#)
- [Full-Text](#)
- [PDF](#)

Open Access

Related Articles

- Should fast breathing pneumonia cases be treated with antibiotics? The scientific rationale for revisiting management in Low and Middle income countries
International Journal of Infectious Diseases Vol. 85
 - [In Brief](#)
 - [Full-Text](#)
 - [PDF](#)
 Open Access
- 'Those who cannot remember the past are condemned to repeat it': Drug-susceptibility testing for bedaquiline and delamanid
International Journal of Infectious Diseases Vol. 80
 - [In Brief](#)
 - [Full-Text](#)
 - [PDF](#)
 Open Access
- Exposed! Management of MDR-TB household contacts in an evidence light era
International Journal of Infectious Diseases Vol. 80
 - [In Brief](#)
 - [Full-Text](#)
 - [PDF](#)
 Open Access
- Li Wenliang, a face to the frontline healthcare worker. The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak
International Journal of Infectious Diseases Vol. 93
 - [In Brief](#)
 - [Full-Text](#)
 - [PDF](#)
 Open Access
- Seroprevalence of antibodies against diphtheria, tetanus, and pertussis among healthy Thai adolescents
International Journal of Infectious Diseases Vol. 96
 - [In Brief](#)
 - [Full-Text](#)
 - [PDF](#)
 Open Access

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the [Use of Cookies](#).

Copyright © 2020 Elsevier Inc. except certain content provided by third parties.

